Clovis Oncology Inc. (NASDAQ:CLVS) was down 5.2% during trading on Thursday . The stock traded as low as $23.30 and last traded at $23.48, with a volume of 1,533,285 shares traded. The stock had previously closed at $24.77.

Several equities research analysts recently commented on CLVS shares. WallachBeth Capital cut their target price on shares of Clovis Oncology from $30.00 to $22.00 and set a “hold” rating on the stock in a research report on Monday, May 9th. Piper Jaffray Cos. restated a “neutral” rating and issued a $14.00 price target on shares of Clovis Oncology in a research report on Thursday, August 25th. Zacks Investment Research downgraded shares of Clovis Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, May 10th. SunTrust Banks Inc. boosted their price target on shares of Clovis Oncology from $25.00 to $30.00 and gave the stock a “buy” rating in a research report on Wednesday, August 24th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $30.00 price target on shares of Clovis Oncology in a research report on Thursday, June 30th. Six analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $30.48.

The company’s 50 day moving average price is $17.01 and its 200 day moving average price is $16.34. The firm’s market capitalization is $908.24 million.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) EPS for the quarter, beating analysts’ consensus estimates of ($2.13) by $0.06. During the same quarter in the prior year, the firm earned ($2.10) EPS. Equities research analysts forecast that Clovis Oncology Inc. will post ($9.33) earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in Clovis Oncology stock. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Clovis Oncology Inc. (NASDAQ:CLVS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 33,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,172,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.09% of Clovis Oncology at the end of the most recent quarter.

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.